Advertisement

Testosterone pp 136-154 | Cite as

Pharmacology of testosterone pellet implants

  • David J. Handelsman

Abstract

The main indication for androgen therapy is the treatment of androgen deficiency in hypogonadal men. Since such androgen replacement therapy usually involves life-long administration of testosterone, it is desirable that testosterone formulations be long-acting. The primary goal of androgen replacement therapy is to replicate the physiological actions of endogenous testosterone. This requires not just rectification of deficient androgen levels but also avoiding either supranormal or excessively fluctuating testosterone levels. Thus the practical intent of androgen replacement therapy is to maintain stable, physiological testosterone levels for prolonged periods. The pharmacological properties of testosterone, notably its rapid metabolic inactivation by the liver, have dictated that the achievement of such prolonged androgenic effects requires the development of depot, sustained-release testosterone formulations (Wilson 1980). Nevertheless, even 50 years after the entry of testosterone into the clinical armamentarium (Hamilton 1937; Foss 1939) the quest for a safe, effective, inexpensive, convenient, long-acting androgen preparation with reproducible, zero-order release profile remains an important challenge not yet met. One of the oldest testosterone formulations is the subdermal implant of testosterone pellets which provide stable testosterone levels for at least 4 months after a single implantation (Cantrill et al. 1984; Conway et al. 1988). Curiously this cheap and effective treatment modality has been neglected for decades despite its many advantages for androgen replacement therapy.

Keywords

Testosterone Level Free Testosterone Testosterone Replacement Therapy SHBG Level Testosterone Propionate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson DC (1974) Sex-hormone-binding globulin. Clin Endocrinol 3: 69–96CrossRefGoogle Scholar
  2. Bishop PMF, Folley SJ (1951) Absorption of hormone implants. Lancet 2: 229–232PubMedCrossRefGoogle Scholar
  3. Biskind GR, Escamilla RF, Lisser H (1941) Implantation of testosterone compounds in cases of male eunuchoidism. J Clin Endocrinol 1: 38–49CrossRefGoogle Scholar
  4. Boylan LM, Conway AJ, Handelsman DJ (1989) Dose and duration characteristics of testosterone pellets in men. Proc Endocrine Society of Australia Annual Scientific Meeting, 32: 34Google Scholar
  5. Burris AS, Ewing LL, Sherins RJ (1988) Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil Steril 50: 493–497PubMedGoogle Scholar
  6. Cantrill J, Dewis P, Large D, Newman M, Anderson DC (1984) Which testosterone replacement therapy? Clin Endocrinol 21: 97–107CrossRefGoogle Scholar
  7. Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11: 247–264PubMedCrossRefGoogle Scholar
  8. Deansley R, Parkes AS (1937) Factors influencing effectiveness of administered hormones. Proc Royal Soc London series B 124: 279–298CrossRefGoogle Scholar
  9. Deansley R, Parkes AS (1938) Further experiments on the administration of hormones by the subcutaneous implantation of tablets. Lancet 2: 606–608CrossRefGoogle Scholar
  10. Deslypere JP, Vermeulen A (1984) Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. 59: 955–962Google Scholar
  11. Dewis P, Newman M, Ratcliffe WA, Anderson DC (1986) Does testosterone affect the normal menstrual cycle? Clin Endocrinol 24: 515–521CrossRefGoogle Scholar
  12. Diaz-Sanchez V, Garza-Flores J, Larrea F, Richards E, Ulloa-Aguirre A, Veayra F (1989) Absorption of dihydrotestosterone ( DHT) after its intramuscular administration. Fertil Steril 51: 493–497PubMedGoogle Scholar
  13. Dorfman RI, Hamilton JB (1941) Rate of excretion of urinary androgens after administration of testosterone by various routes. J Clin Endocrinol 1: 352–358CrossRefGoogle Scholar
  14. Eidelsberg J, Ornstein EA (1940) Observations on the continued use of male sex hormone over long periods of time. Endocrinology 26: 46–53CrossRefGoogle Scholar
  15. Emmens W (1941) Rate of absorption of androgens and estrogens in free and esterified form from subcutaneously implanted pellets. Endocrinology 28: 633–642CrossRefGoogle Scholar
  16. Forbes TR (1941) Absorption of pellets of crystalline testosterone, testosterone propionate, methyl testosterone, progesterone, desoxycorticosterone and stilbestrol implanted in the rat. Endocrinology 32: 70–76CrossRefGoogle Scholar
  17. Foss GL (1939) Clinical administration of androgens. Lancet 1: 502–504CrossRefGoogle Scholar
  18. Foss GL(1942) Implantation of sex hormone tablets in man. J Endocrinol 3: 107–117CrossRefGoogle Scholar
  19. Frey H, Aakvag A, Saanum D, Falch J (1979) Bioavailability of oral testosterone in males. Eur J Clin Pharmacol 16: 345–349PubMedCrossRefGoogle Scholar
  20. Gandy HM (1977) Androgens. In: Fuchs F, Klopper A (eds) Endocrinology of pregnancy, 2nd edn. Harper & Row, Hagerstown, pp 123–156Google Scholar
  21. Gardner FH, Besa EC (1983) Physiologic mechanisms and the hematopoeitic effects of the androstanes and their derivatives. Curr Top Hematol 4: 123–195PubMedGoogle Scholar
  22. Groopman JE, Molina JM, Scadden DT (1989) Hematopoietic growth factors: biology and clinical applications. New Engl J Med 321: 1449–1459PubMedCrossRefGoogle Scholar
  23. Hamilton JB (1937) Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology 21: 649–654CrossRefGoogle Scholar
  24. Hamilton JB, Dorfman RI (1939) Influence of the vehicle upon the length and strength of the action of male hormone substance, testosterone propionate. Endocrinology 24: 711–719CrossRefGoogle Scholar
  25. Handelsman DJ, Conway AJ, Boylan LM, Turtle JR (1984) Testicular function in potential sperm donors: normal ranges and the effects of smoking and varicocele. Int J Androl 7: 369–382PubMedCrossRefGoogle Scholar
  26. Handelsman DJ, Staraj S (1985) Testicular size: the effects of aging, malnutrition and illness. J Androl 6: 144–151PubMedGoogle Scholar
  27. Handelsman DJ, Conway AJ, Boylan LM (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71: 216–222PubMedCrossRefGoogle Scholar
  28. Hellman L, Bradlow HL, Frazell EL, Gallagher TF (1956) Tracer studies of the absorption and fate of steroid hormones in man. J Clin Invest 35: 1033–1044PubMedCrossRefGoogle Scholar
  29. Howard JE, Vest SA (1939) Clinical experiments with male sex hormones. II. Further observations on testosterone propionate in adult hypogonadism, and preliminary report on the implantation of testosterone. Am J Med Sci 198: 823–837CrossRefGoogle Scholar
  30. Kochakian CD (1976) Metabolic effects. In: Kochakian CD (ed) Anabolic-androgenic steroids. Springer, Berlin, pp 5–72 (Handbook of experimental pharmacology, vol 43 )CrossRefGoogle Scholar
  31. Knuth UA, Nieschlag E (1987) Endocrine approaches to male fertility control. In: Burger HG (ed) Clinical endocrinology and metabolism. Bailliere Tindall, London, 1: 113–131Google Scholar
  32. Loeser AA (1940) Subcutaneous implantation of female and male hormone in tablet form in women. Br Med J 479–482Google Scholar
  33. Mooradian AD, Morley JE, Korenman SG (1987) Biological actions of androgens. Endocr Rev 8: 1–28PubMedCrossRefGoogle Scholar
  34. Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, Baez A, Gupta S, Mattoo N (1985) Anemia in chronic renal failure. Acta Endocrinol (Kbh) suppl 271: 80–86Google Scholar
  35. Nieschlag E, Mauss J, Coert A, Kicovic P (1975) Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Kbh) 79: 366–374Google Scholar
  36. Nieschlag E, Cuppers HJ, Wickings EJ (1977) Influence of sex, testicular development and liver function on the bioavailability of oral testosterone. Eur J Clin Invest 7: 145–147PubMedCrossRefGoogle Scholar
  37. Parkes AS (1938) Effective absorption of hormones. Br Med J 371–373Google Scholar
  38. Petra P, Stanczyk FZ, Namkung PC, Fritz MA, Novy ML (1985) Direct effect of sex steroid-binding protein ( SBP) of plasma on the metabolic clearance rate of testosterone in the rhesus macaque. J Steroid Biochem 22: 739–746PubMedCrossRefGoogle Scholar
  39. Reiter T (1963) Testosterone implantation: a clinical study of 240 implantations in ageing males. J Am Geriat Soc 11: 540–550PubMedGoogle Scholar
  40. Rommerts FFG (1988) How much androgen is required for maintenance of spermatogenesis? J Endocr 116: 7–9PubMedCrossRefGoogle Scholar
  41. Southren AL, Gordon GG, Tochimoto S (1968) Further studies of factors affecting metabolic clearance rate of testosterone in man. J Clin Endocrinol Metab 28: 1105–112PubMedCrossRefGoogle Scholar
  42. Swyer GIM (1953) Effects of testosterone implants in men with defective spematogenesis. Br Med J 1080–1081Google Scholar
  43. Thom MH, Collins WP, Studd JWW (1981) Hormonal profiles in postmenopausal women after therapy with subcutaneous implants. Br J Obstet Gynecol 88: 426–433CrossRefGoogle Scholar
  44. Thorn GW, Firor WM (1940) Desoxycorticosterone acetate therapy in Addisons disease. J Am Med Assoc 114: 2517–2525CrossRefGoogle Scholar
  45. Vermeulen AL, Verdonck L, van der Straeten M, Orie N (1969) Capacity of testosterone binding globulin in human plasma and influence of specific binding of testosterone on its metabolic clearance rate. J Clin Endocrinol Metab 29: 1470–1480CrossRefGoogle Scholar
  46. Vest SA, Howard JE (1939) Clinical experiments with androgens. IV: a method of implantation of crystalline testosterone. J Am Med Assoc 113: 1869–1872CrossRefGoogle Scholar
  47. von Schoultz B, Carlstrom K (1989) On the regulation of sex-hormone-binding globulin–a challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem 32: 327–334CrossRefGoogle Scholar
  48. Weinbauer GF, Khurshid S, Fingscheidt U, Nieschlag E (1989) Sustained inhibition of sperm production and inhibin secretion induced by a gonadotropin-releasing hormone antagonist and delayed testosterone substitution in non-human primates ( Macca fascicularis ). J Endocrinol 123: 303–310PubMedCrossRefGoogle Scholar
  49. Wilson JD Griffin JE (1980) The use and misuse of androgens. Metabolism 29: 1278–1295PubMedCrossRefGoogle Scholar
  50. Ying SY (1988) Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 9: 267–293PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • David J. Handelsman

There are no affiliations available

Personalised recommendations